APC/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

BALB/c mouse thymocytes

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^2,3,11 and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)

Product Citations

1. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
3. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
4. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
5. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
6. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
7. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
8. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
9. Pan H, et al. 2020. Mol Psychiatry. . PubMed
10. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
11. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
12. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
13. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
14. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
15. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
16. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
17. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
18. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
19. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
20. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
21. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
22. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
23. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
24. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
25. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
26. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
27. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
28. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
29. Tan X, et al. 2021. Sci Adv. 7: . PubMed
30. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
31. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
32. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
33. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
34. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
35. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
36. Boehm DT, et al. 2019. NPJ Vaccines. 4:40. PubMed
37. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
38. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
39. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
40. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
41. Clement CC, et al. 2021. Immunity. 54:721. PubMed
42. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
43. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
44. Yun H, et al. 2020. Immunity. 53(5):1050-1062.e5. PubMed
45. Ulrich V, et al. 2016. EMBO Mol Med. 8: 643 - 653. PubMed
46. Weng Q, et al. 2018. Cell Regen (Lond). 7:7. PubMed
47. Koide S, et al. 2022. iScience. 25:103603. PubMed
48. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
49. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
50. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
51. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
52. Kumar R, et al. 2020. Cell Reports. 30(8):2512-2525. PubMed
53. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
54. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
55. Howie D, et al. 2019. Front Immunol. 10:1860. PubMed
56. Cobbold SP, et al. 2018. Front Immunol. 9:1381. PubMed
57. Li X, et al. 2021. Front Immunol. 12:779560. PubMed

RRID

AB_312726 (BioLegend Cat. No. 100525)
AB_312727 (BioLegend Cat. No. 100526)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis